Back to Journals » OncoTargets and Therapy » Volume 10

Adverse prognostic impact of TGFB1 T869C polymorphism in non-small-cell lung cancer

Authors Sang Y, Bi X, Liu Y, Zhang W, Wang D

Received 1 October 2016

Accepted for publication 9 November 2016

Published 10 March 2017 Volume 2017:10 Pages 1513—1518

DOI https://doi.org/10.2147/OTT.S123685

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Carlos Vigil Gonzales

Yulan Sang,1 Xin Bi,1 Yan Liu,2 Wei Zhang,1 Dongjie Wang1

1Department of Respiratory, The First Affiliated Hospital of Harbin Medical University, 2Department of Respiratory, The Fourth Hospital of Harbin, Harbin, People’s Republic of China

Abstract: Previously, several polymorphisms in TGFB1 have been identified in non-small-cell lung cancer (NSCLC), and the variants, C-509T, T869C, and G915C, have been demonstrated to associate with higher circulating levels of TGF-β1. However, little is known about the prognostic value of TGF-β1 polymorphisms in cancers. In this study, by genotyping the TGF-β1 T869C polymorphism in a total of 261 patients with NSCLC using DNA from blood lymphocytes, we first found that NSCLC patients, especially those with allele C carriers, had significantly higher serum TGF-β1 levels than healthy individuals. By using chi-square (χ2) test and Fisher’s exact test, we noticed that TC/CC genotypes were positively correlated with smoking, clinical TNM stage, lymph node, and distant metastasis in NSCLC patients. Kaplan–Meier analysis showed that patients with TT genotype had a better overall survival than the allele C carriers (TC + CC). Finally, multivariate analysis confirmed histology, lymph node, and distant metastasis but not T869C polymorphism as independent prognostic factors for NSCLC. Taken together, our data, as a proof of principle, suggest that T869C polymorphism in TGFB1 may act as a genetic modifier in NSCLC progression and a promising prognostic marker of survival in NSCLC patients.

Keywords: genotype and multivariate analysis, single-nucleotide polymorphisms, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]